Abstract
Hepatocellular carcinoma (HCC) causes significant morbidity and high fatal outcome globally. Conventional therapeutic strategies for HCC have achieved significant improvements, but they have limitations and are far from ideal. Novel nanoparticulate drug delivery systems have recently presented great therapeutic potential for cancer therapeutics. Appropriate and accurate animal models (main mice) are the basis of preclinical and translational research of nanoparticulate drug formulations in HCC. This review will provide an overview of different animal models of HCC, with a particular emphasis on those applied to assess the clinical potential for drug nanopharmaceutics.
Keywords: Liver cancer, non-viral nanoparticles, translational research, hepatocellular carcinoma, high fatal outcome, conventional therapeutic.
Pharmaceutical Nanotechnology
Title:The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma
Volume: 6 Issue: 4
Author(s): Zhiwen Zhang, Liu Song and Jianfeng Guo*
Affiliation:
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021,China
Keywords: Liver cancer, non-viral nanoparticles, translational research, hepatocellular carcinoma, high fatal outcome, conventional therapeutic.
Abstract: Hepatocellular carcinoma (HCC) causes significant morbidity and high fatal outcome globally. Conventional therapeutic strategies for HCC have achieved significant improvements, but they have limitations and are far from ideal. Novel nanoparticulate drug delivery systems have recently presented great therapeutic potential for cancer therapeutics. Appropriate and accurate animal models (main mice) are the basis of preclinical and translational research of nanoparticulate drug formulations in HCC. This review will provide an overview of different animal models of HCC, with a particular emphasis on those applied to assess the clinical potential for drug nanopharmaceutics.
Export Options
About this article
Cite this article as:
Zhang Zhiwen , Song Liu and Guo Jianfeng *, The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma, Pharmaceutical Nanotechnology 2018; 6 (4) . https://dx.doi.org/10.2174/2211738506666181001121533
DOI https://dx.doi.org/10.2174/2211738506666181001121533 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
Call for Papers in Thematic Issues
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Hot Topic:Recent Concepts on Cancer- and Metastasis-Initiating Cells and Their Therapeutic Implications in the Development of Novel Effective Cancer Therapies(Guest Editors: M. Mimeault and S.K. Batra) ]
Anti-Cancer Agents in Medicinal Chemistry Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Synthesis and Studies of Anticancer and Antimicrobial Activity of New Phenylurenyl Chalcone Derivatives
Letters in Drug Design & Discovery A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Cell Responses to Oxidative Stressors
Current Pharmaceutical Design The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on CD34+/CD38+ and CD34+/CD38- AML Progenitor Cells
Current Cancer Drug Targets Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents
Drug Design Reviews - Online (Discontinued) Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Higher Levels of Dynamin-related Protein 1 are Associated with Reduced Radiation Sensitivity of Glioblastoma Cells
Current Neurovascular Research Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design